Medicines and PrescribingComplex Medication Changes

Complicated specialist letters, made workable.

A neurology letter changes several medicines over weeks; Reedley separates instructions, gaps and questions, drafts a clarification, and lays out the plan once a clinician confirms it.

Illustrative demonstration · intended workflow
  1. Letter readA specialist letter changing several medicines over weeks
  2. Questions draftedMissing doses and dates go back to the specialist
  3. Plan confirmedDates and quantities follow only from the clinician’s plan

Interactive demonstration

Synthetic patient · pause, step and replay at any point

Complex specialist letters and medication changes

Synthetic data

Reedley structures a complicated change and shows what is missing. The clinician confirms the plan before any directions or quantities exist.

Step 1 of 9 · Specialist letter

A · Synthetic letter, real medicine names, incomplete

  1. Specialist letter
  2. Instructions identified
  3. Current regimen retrieved
  4. Gaps and conflicts flagged
  5. Schedule cannot be dated
  6. Quantities refused
  7. Checks in five states
  8. Review and clarification
  9. Audit: cannot finalise yet
State AReal medicine names · letter incomplete · no dose, interval or quantity the letter does not state
Liam HARTLEYNHS 999 000 2010Born 9 Feb 1992 · 34 y · MaleRecord as at 28 Oct 2026

Prescription directions cannot yet be finalised.

Reading the letter and the medication record. Six checks follow once gaps and conflicts are flagged.

3 need clarification · 2 need clinician review · 1 evidence found.

28 Oct 2026 16:00: 3 need clarification · 2 need clinician review · 1 evidence found.

18 Nov 2026 09:00 · chase date: 3 unresolved · 2 need clinician review · 1 evidence found.

  • Current lamotrigine doseClarification requiredUnresolved
  • Valproate reductionClarification requiredUnresolved
  • Lamotrigine increaseClarification requiredUnresolved
  • Interactions not checkedClinician review requiredReviewed by Dr H. MARSH (synthetic) · 28 Oct 15:10
  • ValproateClinician review requiredReviewed by Dr H. MARSH (synthetic) · 28 Oct 15:10
  • Specialist follow-upEvidence found

Step 1 · Specialist letter

A synthetic neurology letter for Liam HARTLEY arrives (real medicine names).

Neurology clinic letter

Northfield General Hospital (fictional), Department of Neurology

Author
Dr A. RAHMAN, Consultant Neurologist (synthetic)
Clinic
21 Oct 2026
Letter dated
23 Oct 2026
Received
28 Oct 2026 09:40

¶1Diagnosis: juvenile myoclonic epilepsy.

¶2Current medication: sodium valproate 500 mg twice daily and lamotrigine 100 mg twice daily.

¶3I saw Liam in clinic on 21 October 2026. He has had no generalised seizures for over two years and no myoclonic jerks. We discussed his medicines in detail, including the information for male patients taking valproate. He would like to move away from valproate, and we have agreed to withdraw sodium valproate gradually while continuing lamotrigine.

¶4Plan: please reduce the sodium valproate gradually over at least the next three months and then stop it. Once the valproate has been stopped, please increase the lamotrigine to 150 mg twice daily.

¶5We discussed driving and the DVLA guidance during and after withdrawal. He has the epilepsy specialist nurse helpline number and knows to contact us if his seizures increase. I will review him in clinic in four months.

Dr A. RAHMAN, Consultant Neurologist (synthetic)

Step 2 · Instructions identified

The plan’s instructions are extracted; missing values show “Not stated in the letter”.

Sodium valproate

Reduce gradually over at least three months, then stopLetter ¶4

Current dose (letter)
500 mg twice dailyLetter ¶2
Formulation
Not stated in the letterClarification requiredUnresolved
Reduction step
Not stated in the letterClarification requiredUnresolved
Reduction interval
Not stated in the letterClarification requiredUnresolved
Stop date
Not stated in the letterClarification requiredUnresolved

Lamotrigine

Continue; once valproate has stopped, increase to 150 mg twice dailyLetter ¶4

Current dose (letter)
100 mg twice dailyLetter ¶2
Target dose (letter)
150 mg twice dailyLetter ¶4
Start of increase
Not stated in the letterClarification requiredUnresolved
Increase steps
Not stated in the letterClarification requiredUnresolved

Step 3 · Current regimen retrieved

The current repeat entries are retrieved from the record.

The letter states · ¶2

The medication record holds · repeat entries

Step 4 · Gaps and conflicts flagged

The lamotrigine dose conflicts with the record; reduction and increase steps are not stated.

Conflict

Lamotrigine: the letter and the record differ

Gaps

What the letter leaves open

  • Not stated in the letterThe size of each reduction, how often to reduce, the formulation, and the stop date.Letter ¶4Clarification requiredUnresolved
  • Not stated in the letterThe date to start the increase and whether it is made in one step or several.Letter ¶4Clarification requiredUnresolved

Step 5 · Schedule cannot be dated

The schedule is drawn undated, with unknown segments hatched and labelled.

No dates: the letter states none · not to scale

Sodium valproate

Gradual reduction · steps and dates not stated in the letterClarification requiredUnresolved
Stop · date not statedClarification requiredUnresolved

Lamotrigine

Continue · current dose needs clarificationClarification requiredUnresolved
Increase to 150 mg twice daily · start and steps not statedClarification requiredUnresolved
  • “over at least the next three months”Letter ¶4
  • “Once the valproate has been stopped”Letter ¶4
  • “I will review him in clinic in four months.”Letter ¶5

Unknown segments are hatched and labelled. No dates are drawn.

Step 6 · Quantities refused

The demonstration’s calculator refuses: no confirmed doses or dates.

Quantities cannot be calculated: the plan has no confirmed doses and dates.

What the engine needs for each phase, and what the letter gives it
Phase in the letterStartsEndsTimes a dayAmount per dose
Sodium valproate · reduce gradually, then stopFormulation · not stated in the letterRefusedNot stated in the letterRefusedNot stated in the letterRefusedNot stated in the letterRefusedNot stated in the letter
Lamotrigine · continue current doseRefusedNot stated in the letterRefusedNot stated in the letterTwice daily · statedRefusedConflicts with the record
Lamotrigine · increase to 150 mg twice dailyRefusedNot stated in the letterRefusedNot stated in the letterTwice daily · statedRefusedNot stated in the letter

The demonstration’s deterministic calculator returned 11 reasons to refuse and no numbers.

Show the engine’s refusal reasons
  • Sodium valproate: the dispensing unit is not stated.
  • Sodium valproate: phase 1 has no start date.
  • Sodium valproate: phase 1 has no end date.
  • Sodium valproate: phase 1 does not state how many times a day.
  • Sodium valproate: phase 1 does not state the amount per dose.
  • Lamotrigine (current dose): phase 2 has no start date.
  • Lamotrigine (current dose): phase 2 has no end date.
  • Lamotrigine (current dose): phase 2 does not state the amount per dose.
  • Lamotrigine (increase): phase 3 has no start date.
  • Lamotrigine (increase): phase 3 has no end date.
  • Lamotrigine (increase): phase 3 does not state the amount per dose.

Step 7 · Checks in five states

Six checks: 3 clarification required, 2 clinician review required, 1 evidence found; Reviewed and Unresolved appear only at later moments.

Current lamotrigine doseClarification requiredUnresolved

Reedley does not decide which dose is current.

Sodium valproate reduction stepsClarification requiredUnresolved
  • The letter asks for a gradual reduction over at least three months, then stopping.Letter ¶4
  • Not stated in the letterThe size of each reduction, how often to reduce, the formulation, and the stop date.Letter ¶4
  • The record shows sodium valproate 500 mg gastro-resistant tablets, one twice daily.Record · sodium valproate

Reedley does not fill in reduction steps or dates.

Lamotrigine increaseClarification requiredUnresolved
  • The letter states a target of lamotrigine 150 mg twice daily once the valproate has been stopped.Letter ¶4
  • Not stated in the letterThe date to start the increase and whether it is made in one step or several.Letter ¶4

Reedley does not choose increments or dates.

Interactions: not checked by ReedleyClinician review requiredReviewed by Dr H. MARSH (synthetic) · 28 Oct 15:10
  • The letter changes two medicines at once [¶4].Letter ¶4
  • Reedley does not check interactions between medicines. Product information for lamotrigine is linked for the clinician.

Lamictal Tablets SmPC (emc) · last checked 13 Nov 2026

Reedley does not check or evaluate interactions. No flag does not mean no interaction.

ValproateClinician review requiredReviewed by Dr H. MARSH (synthetic) · 28 Oct 15:10

Valproate is named in this letter. Valproate-specific safety requirements may apply · Clinician review required Letter ¶2

MHRA: Valproate – reproductive risks (GOV.UK, last updated 23 Sep 2025) · last checked 13 Nov 2026

Reedley does not evaluate whether any valproate requirement applies or is met.

Specialist follow-upEvidence found
  • The letter states a clinic review in four months, arranged by the neurology team.Letter ¶5

Reedley does not book appointments. “Evidence found” means a passage was found; it is not a judgement and does not close anything.

Step 8 · Review and clarification

A named clinician records review; an editable clarification letter is drafted. Nothing is sent by Reedley.

Clinician review · Dr Helen MARSH, GP (synthetic)

  • Interactions: not checked by ReedleyClinician review requiredReviewed by Dr H. MARSH (synthetic) · 28 Oct 15:10
  • ValproateClinician review requiredReviewed by Dr H. MARSH (synthetic) · 28 Oct 15:10

Reedley does not check or evaluate interactions. No flag does not mean no interaction. Reedley does not evaluate whether any valproate requirement applies or is met.

Not recorded · the clinician records the review

The review is recorded only by the clinician. In the interactive demonstration you record it as Dr Helen MARSH, GP (synthetic).

Draft · not reviewed

Draft for a clinician to edit and send through the practice’s own system. Reedley sends nothing.

Step 9 · Audit: cannot finalise yet

The audit trail records what was read, reviewed and drafted. Prescription directions cannot yet be finalised.

Show as at
  1. 28 Oct 2026 09:40Letter received
  2. 28 Oct 2026 10:05Letter read 28 Oct 2026 10:05; six checks recorded.
  3. 28 Oct 2026Clarification draft prepared for the clinician; sending is the practice’s act.
  4. 28 Oct 2026 15:10Clinician review of the two prompts (interactions not checked by Reedley; valproate) · not recordedClinician review of the two prompts (interactions not checked by Reedley; valproate) recorded by Dr H. MARSH (synthetic) at 28 Oct 2026 15:10, only after the visitor’s action.
  5. 28 Oct 2026 16:00Clarification sent by the practice (sent is not read)
  6. 18 Nov 2026 09:00Chase date for a reply from the neurology teamClarification sent by the practice on 28 Oct 16:00 (sent is not read). No reply found in the available record since 28 Oct 2026; an incomplete record cannot prove that no reply was sent.

No prescription directions, dates or quantities were produced.

See how a confirmed plan is laid out · State B, fictional medicines →

Neurology clinic letter

Dr A. RAHMAN, Consultant Neurologist (synthetic) · dated 23 Oct 2026

Diagnosis · Dr A. RAHMAN, Consultant Neurologist (synthetic)

Diagnosis: juvenile myoclonic epilepsy.

Current medication · Dr A. RAHMAN, Consultant Neurologist (synthetic)

Current medication: sodium valproate 500 mg twice daily and lamotrigine 100 mg twice daily.

Clinic discussion · Dr A. RAHMAN, Consultant Neurologist (synthetic)

I saw Liam in clinic on 21 October 2026. He has had no generalised seizures for over two years and no myoclonic jerks. We discussed his medicines in detail, including the information for male patients taking valproate. He would like to move away from valproate, and we have agreed to withdraw sodium valproate gradually while continuing lamotrigine.

Plan · Dr A. RAHMAN, Consultant Neurologist (synthetic)

Plan: please reduce the sodium valproate gradually over at least the next three months and then stop it. Once the valproate has been stopped, please increase the lamotrigine to 150 mg twice daily.

Advice and follow-up · Dr A. RAHMAN, Consultant Neurologist (synthetic)

We discussed driving and the DVLA guidance during and after withdrawal. He has the epilepsy specialist nurse helpline number and knows to contact us if his seizures increase. I will review him in clinic in four months.

Medication record · repeat entries

Synthetic snapshot as of 28 Oct 2026

Repeat entry

Lamotrigine 50 mg tablets · One twice daily · Repeat · Last issued 2 Oct 2026

Repeat entry

Lamotrigine 25 mg tablets · One twice daily · Repeat · Last issued 2 Oct 2026

Repeat entry

Sodium valproate 500 mg gastro-resistant tablets · One twice daily · Repeat · Last issued 2 Oct 2026

Product literature

Reference only; Reedley does not evaluate it

Product literature

Valproate, which inhibits the glucuronidation of lamotrigine, reduces the metabolism of lamotrigine and increases the mean half-life of lamotrigine nearly two-fold. In patients receiving concomitant therapy with valproate, the appropriate treatment regimen should be used (see section 4.2).

B · Confirmed plan, fictional medicines

  1. Confirmed plan (fictional)
  2. Dated two-track schedule
  3. Draft quantities
  4. Checkpoints for review
  5. Auditable handover
State BFictional medicines · numbers chosen to show the arithmetic; not doses of any real medicineThis is a separate, fictional plan. It is not a completed version of the letter above: the real-drug letter stays incomplete until the specialist replies.
Jordan BAILEYNHS 999 000 2029Born 17 Apr 1985 · 41 yRecord as at 12 Nov 2026

Step 1 · Confirmed plan (fictional)

A separate clinician-confirmed plan with fictional medicines. Not a completed version of the letter above.

Medicine A

  1. 16 Nov 2026 to 22 Nov 202610 mg once dailyPlan ¶2
  2. 23 Nov 2026 to 29 Nov 202610 mg twice dailyPlan ¶2
  3. 30 Nov 2026 to 6 Dec 202620 mg twice dailyPlan ¶2
  4. 7 Dec 2026 to 10 Jan 202740 mg twice dailyPlan ¶2

Medicine B

  1. 16 Nov 2026 to 29 Nov 2026300 mg twice dailyPlan ¶3
  2. 30 Nov 2026 to 13 Dec 2026200 mg twice dailyPlan ¶3
  3. 14 Dec 2026 to 10 Jan 2027150 mg twice dailyPlan ¶3

Confirmed by Dr Helen MARSH, GP (synthetic) · 12 Nov 2026 11:40

Clinician-confirmed inputs (clinician confirmation (synthetic)), not Reedley’s inferences.

Step 2 · Dated two-track schedule

Both medicines on one dated axis: every change date, the shared change on 30 Nov and the turn of the year. Step through the dates.

Confirmed plan · Medicine A and Medicine B on one dated axis

16 Nov 2026 · Medicine A starts 10 mg once daily; Medicine B starts 300 mg twice daily

Medicine A10 mg once dailyChanges on this date

Medicine B300 mg twice dailyChanges on this date

Use Back and Next, or the arrow keys on the chart, to move between dates. On narrow screens the chart scrolls sideways.

Show as a table
TrackFromToDose
Medicine A16 Nov 202622 Nov 202610 mg once daily
Medicine A23 Nov 202629 Nov 202610 mg twice daily
Medicine A30 Nov 20266 Dec 202620 mg twice daily
Medicine A7 Dec 202610 Jan 202740 mg twice daily
Medicine B16 Nov 202629 Nov 2026300 mg twice daily
Medicine B30 Nov 202613 Dec 2026200 mg twice daily
Medicine B14 Dec 202610 Jan 2027150 mg twice daily
Review point23 Nov 202629 Nov 2026Practice review
Review point7 Dec 202613 Dec 2026Practice review
Review point4 Jan 20278 Jan 2027Test X
Review point11 Jan 202711 Jan 2027Specialist review

Step 3 · Draft quantities

One card per strength. Directions, working and quantities come from the demonstration’s deterministic calculator (Reedley’s development build has no quantity calculation); choose a supply period to run it again.

Supply period · the plan’s dates never move

Worked out by the demonstration’s deterministic calculator from the confirmed plan · Whole plan, 16 Nov 2026 to 10 Jan 2027 (56 days)

Swipe sideways for all four strengths.

Medicine A 10 mg tablets

Medicine
Medicine A
Strength
10 mg
Form
tablet
  1. Take ONE tablet ONCE a day for 7 days (16 Nov 2026 to 22 Nov 2026)

    Dates 16 Nov 2026 to 22 Nov 2026Duration 7 daysFrequency Once a day

    Working 16 Nov 2026 to 22 Nov 2026: 7 days × 1 tablet × 1 dose a day = 7 Plan ¶2

  2. Take ONE tablet TWICE a day for 7 days (23 Nov 2026 to 29 Nov 2026)

    Dates 23 Nov 2026 to 29 Nov 2026Duration 7 daysFrequency Twice a day

    Working 23 Nov 2026 to 29 Nov 2026: 7 days × 1 tablet × 2 doses a day = 14 Plan ¶2

  3. Take TWO tablets TWICE a day for 7 days (30 Nov 2026 to 6 Dec 2026)

    Dates 30 Nov 2026 to 6 Dec 2026Duration 7 daysFrequency Twice a day

    Working 30 Nov 2026 to 6 Dec 2026: 7 days × 2 tablets × 2 doses a day = 28 Plan ¶2Confirmation · 12 Nov

Quantity49 tablets7 + 14 + 28 = 49

Medicine B 150 mg tablets

Medicine
Medicine B
Strength
150 mg
Form
tablet
  1. Take TWO tablets TWICE a day for 14 days (16 Nov 2026 to 29 Nov 2026)

    Dates 16 Nov 2026 to 29 Nov 2026Duration 14 daysFrequency Twice a day

    Working 16 Nov 2026 to 29 Nov 2026: 14 days × 2 tablets × 2 doses a day = 56 Plan ¶3

  2. Take ONE tablet TWICE a day for 14 days (30 Nov 2026 to 13 Dec 2026)

    Dates 30 Nov 2026 to 13 Dec 2026Duration 14 daysFrequency Twice a day

    Working 30 Nov 2026 to 13 Dec 2026: 14 days × 1 tablet × 2 doses a day = 28 Plan ¶3Confirmation · 12 Nov

  3. Take ONE tablet TWICE a day for 28 days (14 Dec 2026 to 10 Jan 2027)

    Dates 14 Dec 2026 to 10 Jan 2027Duration 28 daysFrequency Twice a day

    Working 14 Dec 2026 to 10 Jan 2027: 28 days × 1 tablet × 2 doses a day = 56 Plan ¶3Confirmation · 12 Nov

Quantity140 tablets56 + 28 + 56 = 140

Medicine A 40 mg tablets

Medicine
Medicine A
Strength
40 mg
Form
tablet
  1. Take ONE tablet TWICE a day for 35 days (7 Dec 2026 to 10 Jan 2027)

    Dates 7 Dec 2026 to 10 Jan 2027Duration 35 daysFrequency Twice a day

    Working 7 Dec 2026 to 10 Jan 2027: 35 days × 1 tablet × 2 doses a day = 70 Plan ¶2Confirmation · 12 Nov

Quantity70 tablets

Medicine B 50 mg tablets

Medicine
Medicine B
Strength
50 mg
Form
tablet
  1. Take ONE tablet TWICE a day for 14 days (30 Nov 2026 to 13 Dec 2026)

    Dates 30 Nov 2026 to 13 Dec 2026Duration 14 daysFrequency Twice a day

    Working 30 Nov 2026 to 13 Dec 2026: 14 days × 1 tablet × 2 doses a day = 28 Plan ¶3Confirmation · 12 Nov

Quantity28 tablets

Step 4 · Checkpoints for review

Monitoring and review checkpoints from the plan, shown as dated prompts for clinician review.

Monitoring and review points from the plan · dated prompts for clinician review

  1. 23 Nov to 29 Nov 2026Practice review in the week before 30 Nov (both tracks change on 30 Nov) · prompt for clinician reviewClinician review requiredPlan ¶4
  2. 7 Dec to 13 Dec 2026Practice review in the week before 14 Dec · prompt for clinician reviewClinician review requiredPlan ¶4
  3. 4 Jan to 8 Jan 2027Blood test (Test X) between 4 and 8 Jan · prompt for clinician review of the result once receivedClinician review requiredPlan ¶4
  4. 11 Jan 2027Specialist review, arranged by the specialist teamPlan ¶4

Step 5 · Auditable handover

Handover with the plan source, the confirmation, the chosen supply period and the draft directions (copy starts with the DRAFT banner).

  1. 9 Nov 2026Specialist plan dated (fictional medicines)
  2. 12 Nov 2026 11:40Plan confirmed with the specialist team by Dr H. MARSH (synthetic) on 12 Nov 2026.
  3. DraftDraft directions and quantities produced by the demonstration’s deterministic calculator for the chosen supply period; a prescriber issues any prescription in the clinical system. Supply period: Whole plan, 16 Nov 2026 to 10 Jan 2027 (56 days).
  4. DraftFour checkpoints added as dated prompts for clinician review.
  5. CopyDraft directions not copiedDraft directions copied to the clipboard, starting with the DRAFT banner. Nothing was sent or saved.

Draft directions · fictional medicines

Draft · not reviewed

Every strength in the chosen supply period, in order; the preview scrolls.

DRAFT · SYNTHETIC DEMONSTRATION · NOT FOR CLINICAL USE
DRAFT DIRECTIONS — fictional medicines, demonstration only. Supply period: Whole plan, 16 Nov 2026 to 10 Jan 2027 (56 days).

Medicine A 10 mg tablets
Take ONE tablet ONCE a day for 7 days (16 Nov 2026 to 22 Nov 2026)
Take ONE tablet TWICE a day for 7 days (23 Nov 2026 to 29 Nov 2026)
Take TWO tablets TWICE a day for 7 days (30 Nov 2026 to 6 Dec 2026)
Quantity: 49 tablets (7 + 14 + 28 = 49)

Medicine A 40 mg tablets
Take ONE tablet TWICE a day for 35 days (7 Dec 2026 to 10 Jan 2027)
Quantity: 70 tablets

Medicine B 150 mg tablets
Take TWO tablets TWICE a day for 14 days (16 Nov 2026 to 29 Nov 2026)
Take ONE tablet TWICE a day for 14 days (30 Nov 2026 to 13 Dec 2026)
Take ONE tablet TWICE a day for 28 days (14 Dec 2026 to 10 Jan 2027)
Quantity: 140 tablets (56 + 28 + 56 = 140)

Medicine B 50 mg tablets
Take ONE tablet TWICE a day for 14 days (30 Nov 2026 to 13 Dec 2026)
Quantity: 28 tablets

Plan: specialist plan dated 9 Nov 2026 (fictional medicines), confirmed by Dr Helen MARSH, GP (synthetic) on 12 Nov 2026 11:40.
Copied text starts with the DRAFT banner. Copying creates no prescription anywhere.

Copied text starts with the DRAFT banner. Copying creates no prescription anywhere.

Specialist plan · fictional medicines

Dr A. RAHMAN, Consultant Neurologist (synthetic) · dated 9 Nov 2026

About this plan · Dr A. RAHMAN, Consultant Neurologist (synthetic)

This plan uses fictional medicines, Medicine A and Medicine B, to demonstrate the calculation. The numbers are not doses of any real medicine.

Medicine A · Dr A. RAHMAN, Consultant Neurologist (synthetic)

Medicine A: 10 mg once daily from 16 November 2026; 10 mg twice daily from 23 November 2026; 20 mg twice daily from 30 November 2026; 40 mg twice daily from 7 December 2026 until the specialist review.

Medicine B · Dr A. RAHMAN, Consultant Neurologist (synthetic)

Medicine B: 300 mg twice daily from 16 November 2026; 200 mg twice daily from 30 November 2026; 150 mg twice daily from 14 December 2026 until the specialist review.

Review and checkpoints · Dr A. RAHMAN, Consultant Neurologist (synthetic)

Specialist review: 11 January 2027. Please arrange a practice review in the week before 30 November 2026 and in the week before 14 December 2026, and a blood test (Test X) between 4 and 8 January 2027.

Products · Dr A. RAHMAN, Consultant Neurologist (synthetic)

Products: Medicine A 10 mg tablets and 40 mg tablets; Medicine B 150 mg tablets and 50 mg tablets.

Clinician confirmation

Synthetic record entry

Plan confirmed · Dr Helen MARSH, GP (synthetic)

Plan confirmed with the specialist team by telephone. Supply to cover 16 November 2026 to 10 January 2027 inclusive. Medicine A 20 mg doses as two 10 mg tablets; Medicine B 200 mg doses as one 150 mg and one 50 mg tablet.

Synthetic demonstration · fictional patient, clinicians and organisations · NHS number in the 999 test range · Illustrative demonstration · intended workflow · State B uses fictional medicines · Not connected to any clinical system · Nothing is written to a medication record

Illustrative demonstration · intended workflow · Scripted reconstruction: the development build itself is not running on this page.

  • Each instruction linked to the sentence in the letter it came from.
  • Missing doses and dates become questions for the specialist, never guesses.
  • Dates and quantities follow only from a plan a clinician has confirmed.

From what arrives to what you decide

  1. What entersA specialist letter changing several medicines over weeks
  2. What Reedley preparesInstructions, gaps and questions separated, and a clarification drafted
  3. What the clinician decidesA clinician confirms the plan before any dates or quantities

What it does not do · what exists today

  • No dose, interval or quantity is filled in that the letter does not state; dates and quantities appear only on a plan a clinician has confirmed.
  • Valproate is flagged only for clinician review; Reedley does not assess which valproate requirements apply.
  • Instruction comparison and clarification drafts exist in the development build on other letters. The dated plan and quantities are illustrative and use fictional medicine labels.
  • Not yet in Reedley’s intended-purpose register: shown to explore the workflow, not as committed product scope.

Every patient shown is synthetic. No integration with a clinical system is claimed, and no clinician has yet used Reedley in practice. Safety and governance

See it with your own work in mind.

Tell us your role and the workflows you care about, and we will walk you through them on synthetic data.